Tirabrutinib shows 67% response rate in relapsed or refractory primary CNS lymphoma
- In a phase 2 trial, once-daily oral tirabrutinib monotherapy achieved an overall response rate of 67% (95% confidence interval, 52-80) in adults with relapsed or refractory primary central nervous system lymphoma.
- Among 48 enrolled patients with a median follow-up of 11.5 months, the overall response rate was 67% (95% confidence interval, 52-80).
- The complete response rate was 44% (95% confidence interval, 29-59), with a median duration of response of 9.3 months (95% confidence interval, 4.6-14.6).
- The median time to response was 1.0 month, with a range of 0.9 to 3.7.
The publication
In a phase 2 trial, once-daily oral tirabrutinib monotherapy achieved an overall response rate of 67% (95% confidence interval, 52-80) in adults with relapsed or refractory primary central nervous system lymphoma. The study also reported a complete response rate of 44% (95% confidence interval, 29-59) and a median duration of response of 9.3 months (95% confidence interval, 4.6-14.6).
Who the findings apply to
The study enrolled adults with relapsed or refractory primary central nervous system lymphoma in the United States.
Participants were required to have disease that progressed on or after at least one high-dose methotrexate-based therapy.
Why this matters
Primary central nervous system lymphoma is an aggressive subtype of non-Hodgkin lymphoma with a poor prognosis and no established standard of care for relapsed or refractory disease. The trial results indicate that tirabrutinib, a second-generation Bruton tyrosine kinase inhibitor, produced rapid and durable responses in this population, addressing a significant unmet medical need.
What the study found
Among 48 enrolled patients with a median follow-up of 11.5 months, the overall response rate was 67% (95% confidence interval, 52-80).
The complete response rate was 44% (95% confidence interval, 29-59), with a median duration of response of 9.3 months (95% confidence interval, 4.6-14.6).
The median time to response was 1.0 month, with a range of 0.9 to 3.7.
Responses were assessed by an independent review committee in this open-label phase 2 study.
What the result does not establish
Treatment-related treatment-emergent adverse events occurred in 36 patients (75%), most commonly anemia (19%), maculopapular rash (17%), fatigue (15%), neutropenia (15%), lymphocytopenia (15%), pruritus (15%), and other rash (15%).
Grade 3 or higher treatment-related adverse events occurred in 13 patients (27%), most commonly neutropenia (8%) and maculopapular rash (6%).
One death from bronchopulmonary aspergillosis was considered treatment-related.
The study was a single-arm phase 2 trial, so efficacy results are not compared against a control group.
Authors’ conclusion
“In patients with R/R PCNSL, once-daily oral tirabrutinib monotherapy resulted in rapid and durable responses and demonstrated a favorable safety profile. This trial was registered at www.clinicaltrials.gov as NCT04947319.”
Trial registration
| Registered title | Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) |
|---|---|
| Registry status | Phase 2, interventional, active not recruiting |
| Lead sponsor | Ono Pharmaceutical Co. Ltd |
| Registered size | 119 participants — actual enrolment |
| Where | 39 sites in 1 country (United States) |
| Registered primary outcomes |
Primary endpoint named in the abstract: overall response rate (ORR), and secondary endpoints included complete response (CR) rate, duration of response…. Compare the two: a change of primary endpoint after registration matters. |
- Start: Dec 2021
- Paper published: Oct 2026
- Completion: Mar 2027 (estimated)
- Primary completion: Mar 2027 (estimated)
ClinicalTrials.gov record as held by ENCLAI, last updated Oct 2025. The registry status may have changed since; the link shows the current record.
Study and sources
Efficacy and safety of tirabrutinib monotherapy for relapsed/refractory primary CNS lymphoma: PROSPECT phase 2 trial
Early-phase / non-randomised trial · Phase 2 · Blood · 2026-10-01
Sources and limitations
- PubMed record PMID 42821736 (PubMed / NLM · 2026-10-03)
- Trial registry NCT04947319 (ClinicalTrials.gov · 2026-10-03)
Related briefings
Follow ENCLAI News
Get new briefings in your news reader. No ENCLAI account needed.
The daily disease brief
One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.


